header logo image


Page 181«..1020..180181182183..190200..»

Arthritis diet: The surprising food that may cause painful joint inflammation – ‘limit’ – Daily Express

August 17th, 2021 1:48 am

Arthritis is a common condition that causes pain, inflammation and stiffness in a joint. It can be the result of simple wear and tear or autoimmune conditions. What unites the different forms of arthritis is what you can do to mitigate the impact of joint problems.

While theres no miracle diet for arthritis, fortunately, many foods can help fight inflammation and improve joint symptoms.

"For starters, a diet rich in fruits, vegetables, fish, nuts and beans but low processed foods and saturated fat, is not only great for overall health, but can also help manage disease activity," advises the Arthritis Foundation (AF).

Many of these components can be found in a Mediterranean-style diet.

In fact, studies confirm that eating foods commonly part of the Mediterranean diet can benefit your joints as well as your heart, reports AF.

"However, being active can help reduce and prevent pain," notes the NHS.

Regular exercise can also:

"As long as you do the right type and level of exercise for your condition, your arthritis won't get any worse," explains the NHS.

"Your GP can recommend the type and level of exercise that's right for you."

View original post here:
Arthritis diet: The surprising food that may cause painful joint inflammation - 'limit' - Daily Express

Read More...

Primary Cells Market Research Report by Origin, by Cell Type, by End-user, by Region – Global Forecast to 2026 – Cumulative Impact of COVID-19 – Yahoo…

August 4th, 2021 1:55 am

Primary Cells Market Research Report by Origin (Animal Primary Cells and Human Primary Cells), by Cell Type (Dermatocytes, Gastrointestinal Cells, and Heart Cells), by End-user, by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

New York, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Primary Cells Market Research Report by Origin, by Cell Type, by End-user, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06087175/?utm_source=GNW

The Global Primary Cells Market size was estimated at USD 1,025.78 Million in 2020 and expected to reach USD 1,144.46 Million in 2021, at a Compound Annual Growth Rate (CAGR) 11.90% from 2020 to 2026 to reach USD 2,014.78 Million by 2026.

Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:This research report categorizes the Primary Cells to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Origin, the Primary Cells Market was studied across Animal Primary Cells and Human Primary Cells.

Based on Cell Type, the Primary Cells Market was studied across Dermatocytes, Gastrointestinal Cells, Heart Cells, Hematopoietic Cells, Hepatocytes, Lung Cells, Musculoskeletal Cells, and Renal Cells. The Hepatocytes is further studied across Cryopreserved Hepatocytes and Fresh Hepatocytes.

Based on End-user, the Primary Cells Market was studied across Life Science Companies and Research Institutes.

Based on Geography, the Primary Cells Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Primary Cells Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Primary Cells Market, including AcceGen, Allcells, American Type Culture Collection, Axol Bioscience Ltd., BioIVT, Biopredic International, BPS Bioscience, Inc., Cell Biologics, Inc., Corning Incorporated, Creative Bioarray, Epithelix SRL, Ixcells Biotechnologies, Lonza Group AG, Merck KGaA, Neuromics, Ppa Research Group, Inc., Promocell GmbH, Reachbio LLC, Sciencell Research Laboratories, Inc., Sekisui Xenotech, LLC, Stem Cell Technologies, Inc., StemExpress, LLC, Thermo Fisher Scientific, Inc., and Zenbio, Inc..

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:1. What is the market size and forecast of the Global Primary Cells Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Primary Cells Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Primary Cells Market?4. What is the competitive strategic window for opportunities in the Global Primary Cells Market?5. What are the technology trends and regulatory frameworks in the Global Primary Cells Market?6. What is the market share of the leading vendors in the Global Primary Cells Market?7. What modes and strategic moves are considered suitable for entering the Global Primary Cells Market?Read the full report: https://www.reportlinker.com/p06087175/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

View post:
Primary Cells Market Research Report by Origin, by Cell Type, by End-user, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19 - Yahoo...

Read More...

Global Stem Cell Assay Market growth will help industry players with different potential opportunities to explore the market 2021-2027 The Manomet…

August 4th, 2021 1:55 am

TheStem Cell Assay market report offers insights about the marketstatistics based on data collected fromprimary and secondary researchby industry experts. The Global Stem Cell Assay market analysis report gives a detailed overview of the Stem Cell Assay sector, market segmentation, competitive analysis, and major industry developments. The Stem Cell Assay market research study is structured by the latest and most sophisticated methods to capture, process, measure, and evaluate market data. The Stem Cell Assay market report assesses the changing competitive fundamentals based on key market factors. The Stem Cell Assay market forecasts are offered based on historical and future prospects of supply and demand.also, representing the Stem Cell Assay Market Factor Analysis-Porters Five Forces, Supply/Value Chain, PESTEL analysis, CAGR value, product offerings, company landscape analysis, Market Entropy, CAPEX cycle, COGS Analysis, EBITDA analysis,Patent/Trademark Analysis, andPost COVID Impact Analysis.Key Leading Players having extreme Growth Rate in last Few decades includedGE Healthcare, Promega Corporation, Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, Bio-Techne Corporation, Cellular Dynamics International, Cell Biolabs, Hemogenix, Stemcell Technologies.The analysis has listed and evaluated all the key players in the Global Stem Cell Assay Market Compared them on the basis of different metrics such as annual sales shipments volume, historical growth rates, market revenue, and marketing strategies.This Stem Cell Assay industry study report proposes strategic plans to improve market positions for existing market participants.

In addition, the report will also include the computed expected CAGR of the Stem Cell Assay market on the grounds of the prevailing and earlier records in relation to the global market. Moreover, it also offers pin-point analysis for altering the competitive dynamics of the market that can further help in decision-making. It also assists in recognizing the key products and their growth potential during the projected period.

Download Free PDF Sample Report Here:-https://www.syndicatemarketresearch.com/sample/stem-cell-assay-market

( We are Providing a Free Sample copy as per your Research Requirement, also including Covid 19 impact analysis )

Dont miss out on the Analysis of business opportunities in the Stem Cell Assay Market. Speak to our analysts and gain vital industry insights that will help you for your business growth.

Syndicatemarketresearch analysts cover all key parameters required for COVID-19 effect on the business industry, economic implications their trends, factors, consumer behavior on shopping, the effect on spending lot of money on advertising and also on useful industries like medical, transportation, food and Beverage.The globally rising of the Bio crisis COVID-19 has many businesses are struggling and confused on what steps to take to minimize or maximize the economic impact.

Some of the key companies profiled in the global Stem Cell Assay market report include:GE Healthcare, Promega Corporation, Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, Bio-Techne Corporation, Cellular Dynamics International, Cell Biolabs, Hemogenix, Stemcell Technologies

Major parameters covered under these company profiles include revenues, gross profits, operating income, COGS, EBITDA, sales volume, product offerings, company landscape analysis, key strategic moves, key recent developments, and technological roadmap.

The global Stem Cell Assay market has been segmented in the following manner:

By Type:Dermatology Stem Cell Assay, Cardiovascular Stem Cell Assay, Central Nervous System Stem Cell Assay, Oncology Stem Cell Assay, Other

By Application:Regenerative Medicine & Therapy Development, Drug Discovery and Development, Clinical Research, Other

Key regions covered in the world Stem Cell Assay market report include:

The five regions are in a turned segment into major countries and geographies. The key countries included in the global Stem Cell Assay market report includeU.S., Canada, Germany, UK, Italy, France, Spain, China, India, Southeast Asia countries, South Korea, Japan, Australia, GCC countries, Turkey, Brazil, Egypt, Mexico, and South Africa among others.

The main objective of the whole market research report is to help the customer understand business in terms of scope, growth potential, fragmentation, opportunities, key market developments, changing consumer preferences, and new technological trends in the Stem Cell Assay market. The Stem Cell Assay market evaluation report consists of historical and forecasted market data shown by pie charts, maps, graphs, and Phased opportunity analysis in the study.

Key take aways from the report:

To get Free Consultation about Report, Do Inquiry Here @https://www.syndicatemarketresearch.com/inquiry/stem-cell-assay-market

Reasons to buy the global Stem Cell Assay market report:

TOC of Report include-

1 Study Coverage1.1 Stem Cell Assay Product1.2 Key Market Segments in This Study1.3 Key Manufacturers Covered1.4 Market by Type1.4.1 Global Stem Cell Assay Market Size Growth Rate by Type (Dermatology Stem Cell Assay, Cardiovascular Stem Cell Assay, Central Nervous System Stem Cell Assay, Oncology Stem Cell Assay, Other)1.5 Market by Application1.5.1 Global Stem Cell Assay Market Size Growth Rate by Application (Regenerative Medicine & Therapy Development, Drug Discovery and Development, Clinical Research, Other)1.6 Study Objectives1.7 Years Considered

2 Executive Summary2.1 Global Stem Cell Assay Market Size2.1.1 Global Stem Cell Assay Revenue 2013-20252.1.2 Global Stem Cell Assay Production 2013-20252.2 Stem Cell Assay Growth Rate (CAGR) 2018-20252.3 Analysis of Competitive Landscape2.3.1 Manufacturers Market Concentration Ratio (CR5 and HHI)2.3.2 Key Stem Cell Assay Manufacturers2.3.2.1 Stem Cell Assay Manufacturing Base Distribution, Headquarters2.3.2.2 Manufacturers Stem Cell Assay Product Offered2.3.2.3 Date of Manufacturers Enter into Stem Cell Assay Market2.4 Key Trends for Stem Cell Assay Markets & Products

3 Market Size by Manufacturers3.1 Stem Cell Assay Production by Manufacturers3.1.1 Stem Cell Assay Production by Manufacturers3.1.2 Stem Cell Assay Production Market Share by Manufacturers3.2 Stem Cell Assay Revenue by Manufacturers3.2.1 Stem Cell Assay Revenue by Manufacturers (2013-2018)3.2.2 Stem Cell Assay Revenue Share by Manufacturers (2013-2018)3.3 Stem Cell Assay Price by Manufacturers3.4 Mergers & Acquisitions, Expansion Plans

4 Stem Cell Assay Production by Regions4.1 Global Stem Cell Assay Production by Regions4.1.1 Global Stem Cell Assay Production Market Share by Regions4.1.2 Global Stem Cell Assay Revenue Market Share by Regions4.2 United States4.2.1 United States Stem Cell Assay Production4.2.2 United States Stem Cell Assay Revenue4.2.3 Key Players in United States4.2.4 United States Stem Cell Assay Import & Export4.3 Europe4.3.1 Europe Stem Cell Assay Production4.3.2 Europe Stem Cell Assay Revenue4.3.3 Key Players in Europe4.3.4 Europe Stem Cell Assay Import & Export4.4 China4.4.1 China Stem Cell Assay Production4.4.2 China Stem Cell Assay Revenue4.4.3 Key Players in China4.4.4 China Stem Cell Assay Import & Export4.5 Japan4.5.1 Japan Stem Cell Assay Production4.5.2 Japan Stem Cell Assay Revenue4.5.3 Key Players in Japan4.5.4 Japan Stem Cell Assay Import & Export4.6 Other Regions4.6.1 South Korea4.6.2 India4.6.3 Southeast Asia

5 Stem Cell Assay Consumption by Regions5.1 Global Stem Cell Assay Consumption by Regions5.1.1 Global Stem Cell Assay Consumption by Regions5.1.2 Global Stem Cell Assay Consumption Market Share by Regions5.2 North America5.2.1 North America Stem Cell Assay Consumption by Application5.2.2 North America Stem Cell Assay Consumption by Countries5.2.3 United States5.2.4 Canada5.2.5 Mexico5.3 Europe5.3.1 Europe Stem Cell Assay Consumption by Application5.3.2 Europe Stem Cell Assay Consumption by Countries5.3.3 Germany5.3.4 France5.3.5 UK5.3.6 Italy5.3.7 Russia5.4 Asia Pacific5.4.1 Asia Pacific Stem Cell Assay Consumption by Application5.4.2 Asia Pacific Stem Cell Assay Consumption by Countries5.4.3 China5.4.4 Japan5.4.5 South Korea5.4.6 India5.4.7 Australia5.4.8 Indonesia5.4.9 Thailand5.4.10 Malaysia5.4.11 Philippines5.4.12 Vietnam5.5 Central & South America5.5.1 Central & South America Stem Cell Assay Consumption by Application5.5.2 Central & South America Stem Cell Assay Consumption by Country5.5.3 Brazil5.6 Middle East and Africa5.6.1 Middle East and Africa Stem Cell Assay Consumption by Application5.6.2 Middle East and Africa Stem Cell Assay Consumption by Countries5.6.3 GCC Countries5.6.4 Egypt5.6.5 South Africa

6 Market Size by Type6.1 Global Stem Cell Assay Production by Type6.2 Global Stem Cell Assay Revenue by Type6.3 Stem Cell Assay Price by Type

7 Market Size by Application7.1 Overview7.2 Global Stem Cell Assay Breakdown Dada by Application7.2.1 Global Stem Cell Assay Consumption by Application7.2.2 Global Stem Cell Assay Consumption Market Share by Application (2013-2018)

8 Manufacturers ProfilesCompany Name8.1.1 Company Details8.1.2 Company Overview8.1.3 Company Stem Cell Assay Production Revenue and Gross Margin (2013-2018)8.1.4 Stem Cell Assay Product Description8.1.5 Recent Developmentand others

9 Production Forecasts9.1 Stem Cell Assay Production and Revenue Forecast9.1.1 Global Stem Cell Assay Production Forecast 2018-20259.1.2 Global Stem Cell Assay Revenue Forecast 2018-20259.2 Stem Cell Assay Production and Revenue Forecast by Regions9.2.1 Global Stem Cell Assay Revenue Forecast by Regions9.2.2 Global Stem Cell Assay Production Forecast by Regions9.3 Stem Cell Assay Key Producers Forecast9.3.1 United States9.3.2 Europe9.3.3 China9.3.4 Japan9.4 Forecast by Type9.4.1 Global Stem Cell Assay Production Forecast by Type9.4.2 Global Stem Cell Assay Revenue Forecast by Type

10 Consumption Forecast10.1 Stem Cell Assay Consumption Forecast by Application10.2 Stem Cell Assay Consumption Forecast by Regions10.3 North America Market Consumption Forecast10.3.1 North America Stem Cell Assay Consumption Forecast by Regions 2018-202510.3.2 United States10.3.3 Canada10.3.4 Mexico10.4 Europe Market Consumption Forecast10.4.1 Europe Stem Cell Assay Consumption Forecast by Regions 2018-202510.4.2 Germany10.4.3 France10.4.4 UK10.4.5 Italy10.4.6 Russia10.5 Asia Pacific Market Consumption Forecast10.5.1 Asia Pacific Stem Cell Assay Consumption Forecast by Regions 2018-202510.5.2 China10.5.3 Japan10.5.4 South Korea10.5.5 India10.5.6 Australia10.5.7 Indonesia10.5.8 Thailand10.5.9 Malaysia10.5.10 Philippines10.5.11 Vietnam10.6 Central & South America Market Consumption Forecast10.6.1 Central & South America Stem Cell Assay Consumption Forecast by Regions 2018-202510.6.2 Brazil10.7 Middle East and Africa Market Consumption Forecast10.7.1 Middle East and Africa Stem Cell Assay Consumption Forecast by Regions 2018-202510.7.2 GCC Countries10.7.3 Egypt10.7.4 South Africa

11 Value Chain and Sales Channels Analysis11.1 Value Chain Analysis11.2 Sales Channels Analysis11.2.1 Stem Cell Assay Sales Channels11.2.2 Stem Cell Assay Distributors11.3 Stem Cell Assay Customers

12 Market Opportunities & Challenges, Risks and Influences Factors Analysis12.1 Market Opportunities and Drivers12.2 Market Challenges12.3 Market Risks/Restraints12.4 Key World Economic Indicators

13 Key Findings in the Global Stem Cell Assay Study

14 Appendix14.1 Research Methodology14.1.1 Methodology/Research Approach14.1.1.1 Research Programs/Design14.1.1.2 Market Size Estimation14.1.1.3 Market Breakdown and Data Triangulation14.1.2 Data Source14.1.2.1 Secondary Sources14.1.2.2 Primary Sources14.2 Author Details14.3 Disclaimer

Read our other Report:-

Global Ultraviolet (UV) Disinfection Equipment Market Competitive Landscape, with advanced Knowledge and Tactics 2021*2027

https://www.openpr.com/news/2315385/global-rutile-market-statastical-data-analysis-by-market-cap

Contact Us:

Syndicate Market Research

244 Fifth Avenue, Suite N202

New York, 10001, United States

Tel: +49-322 210 92714

USA/Canada Toll Free No.1-855-465-4651

Mail id:sales@syndicatemarketresearch.com

Go here to read the rest:
Global Stem Cell Assay Market growth will help industry players with different potential opportunities to explore the market 2021-2027 The Manomet...

Read More...

US trade and investment in Africa – Brookings Institution

August 4th, 2021 1:55 am

Thank you very much, Chairman Van Hollen, Ranking Member Rounds, and distinguished members of the Subcommittee, for your extraordinary leadership on U.S. Trade and Investment with Africa. Your exemplary bipartisan work on Africa inspires many in the U.S. and abroad on how politics can be used to serve the greater good. I am incredibly honored and grateful for the opportunity offered to me by the members of the Senate Foreign Relations Committees (SFRC) Subcommittee on Africa and Global Health Policy to testify on U.S. Trade and Investment in Africa.

I am Landry Sign, Executive Director and Professor at the Thunderbird School of Global Management, Senior Fellow at the Brookings Institutions Africa Growth Initiative in the Global Economy and Development Program, and a member of the World Economic Forums Regional Action Group on Africa, and the World Economic Forums Global Future Council on Agile Governance.

Advancing trade, investment, and technology in Africa offers enormous economic growth and increased prosperity for both regions and is best realized through value-based foreign policy and a market-based model of development, education, and accountability. There is no better time to accelerate U.S. trade and investment in Africa than now. Despite Africas tremendous economic potential, the U.S. has lost substantial ground to traditional and emerging partners, especially China. Indeed, while recent trends indicate that the U.S. engagement with the region has fallen, it has not and should not cede its relationship with the region to other powers.

Importantly, the U.S. can build on new regional momentum to revive and strengthen its partnership with Africa for mutual prosperity, including building on the recent launch of the African Continental Free Trade Area (AfCFTA), and given the promise of the initiatives of the DFC, Prosper Africa, and the post-AGOA 2025 options. To do so means a shift in emphasis in the relationship to one more focused on value-based foreign policy,1and also building upon the areas of strength and convergence with African citizens preferences;2 such as trade, investment, technology, education, accountability, and a market-based model of development.

Borders frequented by trade seldom need soldiers.

-William Schurz, second President of the American Institute for Foreign Trade (now the Thunderbird School of Global Management)

Trade and investment are not just about money and prosperity. They also bring and support peace, stability, and security. In my book Unlocking Africas Business Potential,3I explore key trade and investment trends, opportunities, challenges and strategies, that illustrate the tremendous potential of Africa, and explain the complex competition between emerging and established powers on the continent. The following key trends are critical for policymaking given their implications for trade investment, economic transformation, inclusive prosperity, geopolitical dynamics, and mutual U.S.-Africa interests.

1. Africas economic transformation and business potential are more substantial than most people think: the worlds next growth market. Considered a hopeless continent in 2000 by The Economist, Africa has seen the two best cumulative successive decades of its existence in the 21st century. Trade in and with Africa has grown 300 percent in the last decade, outperforming global averages (196 percent).4It has become home to many of the worlds fastest-growing economies, offering unique opportunities for U.S. trade and investment. Moreover, Africa has tremendous economic potential and offers rewarding opportunities for local and global partners looking for new markets and long-term investments with some of the highest returns, but also the potential to foster economic growth, diversification, job creation, including for women and youth, and improved general welfare.

2. The fast population growth on the continent could be turned into demographic dividends, or threats to global prosperity and stability. Africa was home to 17 percent of the world population in 2020, and is expected to have 26 percent of the global population in 2050 (2.53 billion people).5If Africa is not successfully integrated into the global economy, there could be a major threat to global prosperity and stability. Citizens could be further subject to extreme poverty, fragility, violent extremism, illegal immigration, health challenges, among otherschallenges that many already face on the continent. If our goal is a prosperous and safe world, Africa must not be left behind.

3. The growth of household consumption and business spending: a unique opportunity for U.S. trade and investment. By 2050, Africa will be home to an estimated USD 16.12 trillion of combined consumer and business spending.67 And Africas prosperity can be good for the U.S.: Such growth will offer tremendous opportunities for U.S. businesses in household consumption (USD 8 trillion) in areas such as food and beverages, housing, hospitality and recreation, health care, financial services, education and transport, and consumer goods, but also business to business spending (construction, utility, and transportation, agriculture and agri-processing, wholesale and retail, etc.).

4. The rise of global partnerships and the competition between traditional and new players: an opportunity for the U.S. to build on its sustainable competitive advantage. In 2009, China became the regions prime trading partner. In fact, between 2006 and 2016, Chinas trade with Africa surged, with imports increasing by 233 percent and exports increasing 53 percent, as they did for several other global players as well.8 During the same period, the U.S. lost ground in exports to Africa (-66 percent).9

Chinas influence goes beyond the trade relationship: It is also the top investor in infrastructure, and now is the first destination of English-speaking African students, outperforming the U.S. and the U.K.10

Change (increase) in imports from Africa,

2006 2016

Change (increase) in exports to Africa,

2006 2016

Source: IMF, Direction of Trade Statistics, 2017.11

But the U.S. remains a critical player on the continent, as I mentioned in a recent article: Successes in the past decadesinitiatives such as the African Growth and Opportunity Act (AGOA), the Presidents Malaria Initiative, the Presidents Emergency Plan for AIDS Relief, the Millennium Challenge Corporation, and U.S. trade and investment hubshave generated tremendous opportunities for millions of Africans and Americans. But the current eraand competition from other global powerswill require new ideas and a new approach to several key issues.12 In fact, African countries would often prefer to work with the U.S. given local content regulation rules, more investment in on-the-ground resources, and standards about hiring/training locals. In other words, the U.S. is less extractive and more transparent than numerous other partners.

5. Fast urbanization but also fast rural population growth: By 2030, Africa will be home to 5 cities of more than 10 million inhabitants and 12 other cities of more than 5 million inhabitants.13 Cities in Africa are becoming powerful economic centers, and a city-based approach to foreign policy, but also trade and investment, will be critical to outperform competitors and build mutual prosperity. Contributing to the prosperity of African cities will also make a difference in addressing security challenges.

6. Africa has made tremendous progress in mobilizing resources for infrastructure development, working hard to bridge gaps in ICT, energy, water and sanitation, and transportation. Despite the remaining deficits, the Infrastructure Consortium for Africa (ICA) reported that between 2013 and 2017 the annual funding for infrastructure development in the region was USD 77 billion, about twice as much as the annual funding average of the first six years of the 2000s.14 However, many of these gaps persist. In 2018 the African Development Bank (AfDB) found that Africas infrastructure requirements are between USD 130 and 170 billion a year, leaving a financing gap of USD 68 to108 billion.15 China has played a key role in financing, and has become the largest bilateral infrastructure financer in Africa (Chinese FDI grew 40 percent annually from 2010 to 2020).16 However, the U.S. has the chance to make a monumental difference when it comes to investing in infrastructure development in Africa.

In fact, Africa has one of the fastest-growing, and is the second-largest, mobile phone market in the world.1718 In sub-Saharan Africa alone, there were 477 million mobile subscribers in 2019; by 2025, the region will host 614 million cell phone subscribers, and 475 million mobile internet users.19 The internet is also expected to contribute to at least 5 to 6 percent of Africas total GDP by 2025.20 While the Information and Communication Technology sector is making incredible advancements, water and sanitation, transportation, and energy infrastructure development still needs significant investment. However, this is indicative of positive and extensive investment opportunities that can be undertaken on the African continent.

7. Fast digitalization, increased technological innovation, and an accelerated Fourth Industrial Revolution (4IR): The Fourth Industrial Revolution is characterized by the fusion of the digital, biological, and technological world, and technologies such as artificial intelligence, big data, 5G, drones and automated vehicles, and cloud computing.21 As a world leader in technological innovation, digital transformation, and the Fourth Industrial Revolution, the United States is well-positioned to play a leading role in the African digital space and contribute to Africas pursuit of now-vital technologies.

Indeed, advanced technology can have beneficial spillover effects: For example, in health, countries such as Rwanda and Ghana are using an American drone company Zipline to deliver, in record time, medication, blood, and medical supplies to remote rural areas with limited road accessibility.22 In agriculture, African farmers now have access to affordable precision farming tools that use sensors, satellites, smart devices, and big data technologies to inform every decision. The lending, insurance, and e-commerce opportunities provided by the fintech industry are transforming the lives of all Africans, and not just those in urban centers. These advancements are just the beginning too, as African entrepreneurs are increasingly seeking partners to bring transformative businesses to life. African tech startup funding increased over 40 percent in 2020 to over USD 700 million, a fraction of tech startup funding outside of Africa. Despite such progress, the digital divide remains important and must be bridged to allow inclusive development. During the pandemic, for example, access to school and business on the continent was more complex given the level of internet connectivity, among other limitations. Bridging the digital divide represents an opportunity to both advance U.S. trade and investment in Africa while addressing some of Africas key priorities.

8. Fast regional integration and the African Continental Free Trade Areas: opportunities for a continental engagement. With the signing of the African Continental Free Trade Area (AfCFTA) in 2018, ratification in 2019, and an official launch in January 2021, African growth prospects and business opportunities have been magnified. The continent is giving the world just one more reason to invest in it with the creation of the largest new free-trade zone per number of countries in world, since the creation of the WTO. The AfCFTA will accelerate Africas industrialization as well as incomes, which will lead to the increase of both household consumption and business spending, generating unique opportunities for U.S. trade and investment. Per a World Bank study, the AfCFTA has the potential to lift 30 million people out of extreme poverty, increase the income of 68 million Africans, increase Africas exports by USD 560 billion, and generate USD 450 billion of potential gains for African economies by 2035.23

9. The sustained demand for accountability, democracy, and stability of African citizens, and policy priorities aligned with U.S. core values. Per Afrobarometer surveys, 7 out of 10 Africans support democracy and accountable governance, and approximately two-thirds are opposed to a single party or military government.24 Importantly, areas in which the U.S. has a sustained competitive advantage, given its global leadership in democracy and human rights, and its support for such issues as health and education, are priorities for Africans too.25Given Chinas leadership in infrastructure, the U.S. could grow its footprint in this area but by partnering with other players such as the G7 and the European Union countries. This approach will be welcomed by African citizens, who prefer the U.S. model of development (32 percent) over the Chinse one (23 percent).26

The pandemic has created unique momentum for engagement with Africa. The U.S. should seize this momentum and build on Congress historical bi-partisan support for the region to develop and successfully implement a long-term comprehensive Africa strategy that effectively coordinates action around trade, investment, commerce, and economic growth. This strategy should draw from consultations with African partners and multilaterals, building on areas of sustainable competitive advantages. The strategy should:

a) be rooted in the American values and principles that are aligned with the priorities of African citizens and U.S.-Africa mutual trade and investment interests

b) protect American, African, and global interests by advancing security, stability, and peace through strategic partnerships with African organizations

c) utilize U.S. strengths (digital transformation, Fourth Industrial Revolution, education, creative industries, health, democratic values, etc.) in the context of the new continental trade dynamics brought about by the African Continental Free Trade Areas (AfCFTA).

Importantly, these are areas where the U.S. can still outperform its main competitors such as China or Russia. More specifically, my recommendations to the Subcommittee are as follows:

1. Build on multilateralism and strategic alliances in concert with African partners to advance U.S. and African interests.

Given Africas own emphasis on regionalism, the U.S. would do well to support those efforts and align its own strategy with this perspective in mind. Core African partners include: the African Union, the African Continental Free Trade Area, the Africa Centres for Disease Control and Prevention, the African Union Development Agency, the African Development Bank, among others.

African leaders are looking for partners, especially in terms of trade and investment, more than they need aid. Initiatives from the Millennium Challenge Corporation and the DFC should further support African regional and continental projects, when possible, through regional compacts (MCC, through the 2018 AGOA and MCA Modernization Act, allows investments to be made across borders in Africa, creating opportunities for trade and investment by fostering regional integration and integrated markets).27 For the U.S. to outperform its competitors, it must be on the ground engaging with Africa both at the base but also at the highest levels, building on the Trade and Investment hubs, but going much further.

2. Enhance the effectiveness and better coordinate the action of U.S. agencies acting around trade and investment in Africa by adopting the principle of agile governance.

The U.S. already has phenomenal tools, which in principle, could make a monumental difference if successfully implemented. Prosper Africa holds a lot of potential in terms of trade, investment, shared prosperity, and effective coordination of U.S. agencies, which is not yet realized. The goal of Prosper Africa is to coordinate the tools from across government agencies28 and to foster trade and investment between the U.S. and Africa. Although it is a great idea, many players, especially on the African side, are still hoping for it to achieve its full potential. It will be extremely important to have major wins to reinstate trust with African partners.

I recommend making Prosper Africa more agile in its ability to manage complexity and competition, and appoint a dedicated full-time Chief Executive Officer to assist the current Executive Chairman and Chief Operating Officer, who are doing tremendous work. This new position should have the authority needed to fix the pacing (appropriate speed of action), coordination (legitimate and appropriate coordination), and representation challenges (uniqueness of the voice, communication, and acceptance of the credibility), to deliver exceptional outcomes for U.S. and African businesses, and investors, to achieve mutual prosperity.

3. Redefine the base for new engagement with Africa by appointing a U.S. Special Presidential Envoy for Africa to represent the U.S. at high-level meetings and multiply presidential and high-level visits in Africa.

To stop ceding ground to other powers in Africa, it is crucial that the U.S. reiterate the respect it has for Africa, Africans, and their leaders. Appointing a Special Envoy and reinstating high-level meetings, including presidential visits to the region, between the United States and Africa will send a strong signal. Regular visits by senior U.S. officials, including the President and his cabinet, will help to shift perceptions around Africa, highlighting the continent as a safe, reliable destination for investment. Creating a forum for dialogue between government officials and the SME community will create the opportunity to engage in a systematic and coordinated way.29

Advancing such levels of engagement, with specific actions, will substantially advance mutual interests. The U.S. should build on this to further institutionalize relations with Africa and engagements at the highest level. The success of the U.S.-Africa Business Forum, which did contribute to deals around USD 14 billion between 2014 (first edition) and 2016, with additional deals and commitments of USD 9 billion at the 2016 edition, illustrate the importance of high-level meetings, which should be reinitiated (The first edition of the U.S.-Africa Business Forum was attended by about 50 heads of state and governments, and 150 global CEOs).

This is not just important for African leaders, but also for African citizens who prefer the U.S. model of development compared to any other country.30Strategically seizing such as opportunity to build a long-term sustainable advantage will be critical.

4. For the successful implementation of the AfCFTA and other critical initiatives (post-2025 AGOA, among others) the U.S. should be involved in regular high-level consultations between the United States Trade Representative, the AfCFTA, and the African Union, creating a working group which could define the critical steps forward.

It is important to engage with Africa on the way forward about U.S.-Africa relations, through regular consultations. The AfCFTA offers new opportunities for U.S. businesses to use Africa as a global platform, not just to capitalize on the large African market, but to benefit from the unique advantage provided to sell around the world. The U.S. will also gain market shares, etc. Africa can become the base for U.S. companies to trade not just with Africa, but with the world as well. Africa is not just a market, but also a platform to manufacture and export in other regions of the world. The AGOA Forum provides a platform to discuss these questions in partnership with Africans, but it remains underutilized.

5. The U.S. should capitalize on the AfCFTA that provides the opportunity for the U.S. and the world to finally address the global macroeconomic imbalances which have been reflected in structurally large U.S. current account deficits with a handful of countries largely on account of excessive concentration of supply chains.31

The growth opportunities associated with increasing economies of scale and productivity growth under the AfCFTA provides the path to reorder and diversify the supply chains for greater resilience and while also sustainably addressing the macroeconomic imbalances which have dominated the world economy over the past decades.

Already several countries and corporations are taking advantage of growth opportunities offered by the AfCFTA in the automotive industry. Volkswagen has opened its first car plant in Rwanda.3233 Groupe Peugeot Socit Anonyme has established its first plant to assemble up to 5000 cars a year in Namibia, taking advantage of the free market area to target customers in other countries across the region.34 With its population growth and rising middle class, Africa could well become the largest market for the automotive industry in the coming decades.

These are tremendous opportunities that U.S. carmakers, including those manufacturing less polluting new energy vehicles should be targeting, especially with Africas excess reserves of lithium and coltan which are some of the most important raw materials for a rapidly changing industry.

6. Focus policy action on impact, and on the effective implementation and delivery of initiatives, not just on big policy announcements.

The U.S. should distinguish itself by focusing on successful implementation of existing or new initiatives. For example, the G7 countries and partners have announced an USD 80 billion dollars commitment for Africas private sector for the next five years. How will it be implemented? It is critical to have a clear mechanism for successful implementation that includes sufficient details about the projects. For example, the U.S. and partners should engage with African multilaterals (AfCFTA, AU, etc.) and governments during the policymaking and implementation processes to strategically identify and align objectives. An implementation unit may be created, and a multistakeholder working group to assess and decide on mutual priorities. Similarly, how could the Build Back Better World initiative be successfully implemented, and to what extent will Africa benefit from it? The administration needs to appoint a leader to strategically engage and to have consultations with allies. Bringing the allies together, and giving teeth to the plans that have been put together, will be critical to build sustainable competitive advantage for the U.S.

7. The U.S. should promote commercial diplomacy through an economic strategy that goes beyond the traditional vision of trade and investment. Domestically, the U.S. should increase efforts to document and disseminate the tremendous potential Africa can have for U.S. businesses.

Given that a central goal of Prosper Africa is to double two-way trade, the United States should play a better role in identifying and sharing business and investment opportunities with its domestic businesses and corporations. As large corporations are already better resourced when dealing in Africa, American SMEs are the most likely beneficiaries of Prosper Africawhether through market access or on the supply sideand the DFC should provide them with resources to help trade and invest in a timely manner. For Prosper Africa to benefitboththe U.S. and Africa, each side needs to feel confident in the trading process and consider each other a friend.

Prosper Africa should focus on specific mechanisms aimed at ensuring that American SMEs better understand the dynamics in Africa, to develop a specific interest and attraction on the continent and make others more eager to invest and do business there. This goal can be achieved throughbusiness promotion and facilitation activities encouraging business development as well as corporate diplomacy.

8. The U.S. should capitalize on the African Diaspora, which is heavily represented and active in the U.S., by specifically adopting diaspora commercial diplomacy to foster trade and investment between the U.S. and Africa.

President Biden has made steps in strengthening this relationship through early engagement with the community, but this strategy can be pursued further in regard to trade and investment with Africa in order to distinguish the U.S. from other competitors and accelerate its competitive advantage. The collaborations between African innovators on the continent and African and African-American innovators based in the U.S. have the potential to advance U.S.-Africa relations on several levels.35 Members of the African diaspora have an incredibly valuable understanding of Africa-U.S. cross-cultural engagement, not to mention existing relationships and networks on the continent, making them perhaps the best suited to Prosper Africas efforts to support and facilitate business I mentioned above. Prosper Africa should formalize a relationship with the African diasporas SME community and the continents SME community, and routinely engage as a group, to support the formulation of strategies and mechanisms to increase two-way trade. It has started such an effort, but can do more: For example, in 2019, Brookings hosted a conversation between USAID and members of the diasporas SMEs. It brought to light specific, actionable ways to enhance the programs mechanisms, including the need to expand staff support at trade hubs, expedite DFC loans, and improve data collection and analysis.36 SMEs in Africa are crucial to include in these conversations so that all stakeholders are involved to ensure Prosper Africa designs effective, efficient policies.

9. Accelerate the COVID-19 vaccine strategy and partnerships, and aggressively pursue vaccine diplomacy beyond COVID-19 by supporting the development of a vaccine manufacturing industry in Africa, including investments in human capital and technology development.37

According to the Africa Centers for Disease Control and Prevention (Africa CDC), only 3.19 percent of Africans have received at least one dose of the COVID-19 vaccine as of July 21, 2021.38 A Duke University study estimated that most Africans will not have had an opportunity to receive the COVID-19 vaccine until 2024.39 The devastation of the COVID-19 pandemic, as well as other epidemics in recent years like, has revealed the urgent need for investment in Africas national and continental healthcare systems. Vaccine diplomacy is a crucial first step towards helping Africa recover from the pandemic and prevent the emergence of new variants that might damage the recoveries in other nations.

While it is the right thing to do, it will also support U.S. businesses. Poor healthcare systems threaten Africas industrialization and workforce development, and now is the opportunity for the U.S. to help build equitable health systems and ensure preparedness for future health emergencies. This support should not be limited to loans or donations. Partnerships with academic institutions or public-private partnerships between U.S. and African agencies and firms that create avenues for collaboration, knowledge exchange, and skill and technology development will all be instrumental in strengthening the soft power of the U.S.

Specifically, the U.S. should provide broad technical and financial support for the new African Union-Africa CDC initiative, Partnerships for African Vaccine Manufacturing (PAVM), which aims to build five vaccine-manufacturing research centers over the next 10-15 years. The success of this PAVM initiative would open doors for a transformation of Africas pharmaceutical industry in Africa, a sector that has enormous growth potential. The development must go beyond fill and finish manufacturing, which does little to truly decrease Africas overreliance on foreign suppliers.40

10. Contribute to closing the gap in the physical and digital infrastructure by leveraging existing programs supporting African countries digital transformation strategies.41

The U.S. already has established infrastructure and technology development programs, but is underutilizing them. Such initiatives, especially those that focus on electricity and internet penetration, should be prioritized and fast-tracked.42

Most importantly and prior to even leveraging these existing initiatives, the U.S. should consult and act in partnership with African countries for the investments in major infrastructures, including 5G. For example, an opportunity is within OPIC [now DFC]s Connect Africa initiative, which was launched with a fund of USD 1 billion for transportation, ICT, and value chain development projects.43 The Power Africa initiative has been successful, and augmenting the program now would contribute to repairing and strengthening the U.S.-Africa relationship.44

Furthermore, several African countries are developing and implementing a multi-stakeholder Fourth Industrial Revolution (4IR) national task force or commission to assess country readiness and adopt a comprehensive national strategy. Initiatives such as the Centers for the Fourth Industrial Revolution (South Africa and Rwanda), or the Presidential Commission on the 4IR (South Africa) should be supported and replicated across the continent.

11. The U.S. must continue and increase its support to bridging the infrastructure gap in Africa while advancing trade and investment for mutual prosperity.

This, simultaneously, represents both a way forward to enhance trade and investment while achieving the global public good. In fact, in Sub-Saharan Africa, over 50 percent of people live without access to electricity, more than 70 percent of people live without access to safe drinking water, 69 percent of people live without basic sanitation,45 and 53 percent of the roads are unpaved.46 China has been playing a central role by investing in these areas.

Importantly, the U.S. should differentiate its approach from competitors by emphasizing engagement with African continental organizations (PIDA, the AFDB, the African Development Fund, among others), bilaterallyand more importantly, transparently, with specific countries, and by partnering with allies. The U.S. also could better support capacity building and regional projects through investments, new projects, and partnerships. The U.S. could better partner with Africa to bring its own expertise and knowledge to serve at various phases of project development, such as studies and implementation.47 A long-term partnership will also be key to outperforming other players. The U.S. will see a high return for its investments, as well as geostrategic balance. The U.S. will fill an empty seat, that would otherwise be occupied by other players on the continent.

12. The U.S. can build on higher education, another area of comparative advantage, to provide technical training and reskilling programs through initiatives and agencies to close the digital skills gap and human capital gap (especially for youth and women).48

It is crucial the U.S. expand educational and training opportunities in Africa. The soft skills and development of academic institutions provide the opportunity for the U.S. to lay the foundation for a lasting win-win partnership with Africa, sustained by knowledge exchange and deepening business ties. U.S. policy needs to provide support that incentivizes American universities to open more campuses and degree programs, especially in STEM and technology, throughout Africa. Such programs provide skills in areas critical for the rise of manufacturing industry and effective decentralisation of global supply chains and will be equally beneficial learning opportunities for African students and American students who may study abroad. For example, Carnegie Mellon University has a campus in Rwanda that offers masters programs in information technology and electrical and computer engineering.49 Morgan State University has recently launched a partnership with a university in Ghana, offering two graduate degree programs to students.50 Fast-growing SMEs will be far more likely to evolve and invest in areas where there is a skilled workforce or, at least, resources to support training workers, and added U.S. support could go a long way towards creating an attractive business environment for SME investment. It is indeed an opportunity to establish a long-term partnership of a new nature between U.S. and Africa.

In closing, it is time for U.S. to reverse the trend in the ground lost in Africa as many traditional and emerging global powers are racing to capture Africas tremendous economic potential. The U.S. has a sustained competitive advantage to partner with Africa, advance U.S. trade and investment with the continent, while meeting the majority of Africans priorities. It is up to the U.S. to pursue the recommendations above and seize this unique momentum to advance mutual U.S.-Africa trade and investment interests. By acting promptly, and forging transformative partnerships aligned with African values, the U.S. has the opportunity to not only advance its own interests and contribute to the transformation of a continent that will make up nearly 40 percent of the worlds population by 2100, but also the opportunity to lead the way in building a more prosperous, democratic, secure, and stable world. As mentioned by William Schurz, borders frequented by trade seldom need soldiers.

Thank you very much for your attention and looking forward to your questions.

Continued here:
US trade and investment in Africa - Brookings Institution

Read More...

Half Abandon Metformin Within a Year of Diabetes Diagnosis – Medscape

August 4th, 2021 1:54 am

Nearly half of adults prescribed metformin after a new diagnosis of type 2 diabetes have stopped taking it by 1 year, new data show.

The findings, from a retrospective analysis of administrative data from Alberta, Canada, during 2012-2017, also show that the fall-off in metformin adherence was most dramatic during the first 30 days, and in most cases, there was no concomitant substitution of another glucose-lowering drug.

While the majority with newly diagnosed type 2 diabetes were prescribed metformin as first-line therapy, patients started on other agents incurred far higher medication and healthcare costs.

The data were recently published online in Diabetic Medicine by David J. T. Campbell, MD, PhD, of the University of Calgary, Alberta, Canada, and colleagues.

"We realized that even if someone is prescribed metforminthat doesn't mean they're staying on metformin even for a year...the drop-off rate is really quite abrupt," Campbell told Medscape Medical News. Most who discontinued had A1c levels above 7.5%, so it wasn't that they no longer needed glucose-lowering medication, he noted.

One reason for the discontinuations, he said, is that patients might not realize they need to keep taking the medication.

"When a physician is seeing a person with newly diagnosed diabetes, I think it's important to remember that they might not know the implications of having a chronic condition. A lot of times we're quick to prescribe metformin and forget about it...Physicians might write a script for 3 months and three refills and not see the patient again for a year...We may need to keep a closer eye on these folks and have more regular follow-up, and make sure they're getting early diabetes education."

Side effects are an issue, but not for most. "Any clinician who prescribes metformin knows there are side effects, such as upset stomach, diarrhea, and nausea. But certainly, it's not half [who experience these]...A lot of people just aren't accepting of having to take it lifelong, especially since they probably don't feel any better on it," Campbell said.

James Flory, MD, an endocrinologist at Memorial Sloan Kettering Cancer Center, New York City, told Medscape Medical Newsonly about 25% of patients taking metformin experience gastrointestinal side effects.

Moreover, he noted that the drop-off in adherence is also seen with antihypertensive and lipid-lowering drugs that have fewer side effects than metformin. He pointed to a "striking example" of this, a 2011 randomized trial published in the New England Journal of Medicine, and as reported by Medscape Medical News, showingoverall rates of adherence to these medications was only around 50%, even among people who had already had a myocardial infarction.

"People really don't want to be on these medications...They have an aversion to being medicalized and taking pills. If they're not being pretty consistently prompted and reminded and urged to take them, I think people will find rationalizations, reasons for stopping...I think people want to handle things through lifestyle and not be on a drug," noted Flory, who has also published on the subject of metformin adherence.

Moreover, Flory explained, "These drugs don't make people feel better. None of them do. At best they don't make you feel worse. You have to really believe in the chronic condition and believe that it's hurting you and that you can't handle it without the drugs to motivate you to keep taking them."

Communication with the patient is key, he said.

"I don't have empirical data to support this, but I feel it's helpful to acknowledge the downsides to patients. I tell them to let me know [if they're having side effects] and we'll work on it. Don't just stop taking the drug and never circle back." At the same time, he added, "I think it's important to emphasize metformin's safety and effectiveness."

For patientsexperiencing gastrointestinal side effects, options including switching to extended-release metformin or lowering the dose.

Also, while patients are typically advised to take metformin with food, some experience diarrhea when they do that and prefer to take it at bedtime than with dinner. "If that's what works for people, that's what they should do," Flory advised.

"It doesn't take a lot of time to emphasize to patients the safety and this level of flexibility and control they should be able to exercise over how much they take and when. These things should really help."

Campbell and colleagues analyzed 17,932 individuals with incident type 2 diabetes diagnosed between April 1, 2012 and March 31, 2017. Overall,89% receivedmetformin monotherapy as their initial diabetes prescription, 7.6% startedmetformin in combination with another glucose-lowering drug, and 3.3% were prescribed a nonmetformin diabetes medication. (Those prescribed insulin as their first diabetes medication were excluded.)

The most commonly coprescribed drugs with metformin were sulfonylureas (in 47%) and DPP-4 inhibitors (28%). Of those initiated with only nonmetformin medications, sulfonylureas were also the most common (53%) and dipeptidyl peptidase-4 (DPP-4) inhibitorssecond (21%).

The metformin prescribing rate of 89% reflects current guidelines, Campbell noted.

"In hypertension, clinicians weren't really following the guidelines...they were prescribing more expensive drugs than the guidelines say...We showed that in diabetes, contrary to hypertension, clinicians really are generally following the clinical practice guidelines...The vast majority who are started on metformin are started on monotherapy. That was reassuring to us. We're not paying for a bunch of expensive drugs when metformin would do just as well," he said.

However, the proportion who had been dispensed metformin to cover the prescribed number of days dropped by about 10% after 30 days, by a further 10% after 90 days, and yet again after 100 days, resulting in just 54% remaining on the drug by 1 year.

Factors associated with higher adherence included older age, presence of comorbidities, and highest versus lowest neighborhood income quintile.

Those who had been prescribed nonmetformin monotherapy had about twice the total healthcare costs of those initially prescribed metformin monotherapy. Higher healthcare costs were seen among patients who were younger, had lower incomes, higher baseline A1c, had more comorbidities, and were men.

Campbell noted that "a lot has changed since 2017...At least in Canada, the sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists were supposed to be reserved as second-line agents in patients with cardiovascular disease, but more and more they're being thought of as first-line agents in high-risk patients."

"I suspect as those guidelines are transmitted to primary care colleagues who are doing the bulk of the prescribing we'll see more and more uptake of these agents."

Indeed, Flory said, "The metformin data at this point are very dated and the body of trials showing health benefits for it is actually very weak compared to the big trials that have been done for the newer agents, to the point where you can imagine a consensus gradually forming where people start to recommend something other than metformin for nearly everybody with type 2 diabetes. The cost implications are just huge, and I think the safety implications as well."

According to Flory, the SGLT2 inhibitors "are fundamentally not as safe as metformin. I think they're very safe drugs large good studies have established that but if you're going to give drugs to a large number of people who are pretty healthy at baseline the safety standards have to be pretty high."

Just the elevated risk of euglycemic diabetic ketoacidosis alone is reason for pause, Flory believes. "Even though it's manageable...metformin just doesn't have a safety problem like that. I'm very comfortable prescribing SGLT2 inhibitors, but If I'm going to give a drug to a million people and have nothing go wrong with any of them, that would be metformin, not an SGLT2 [inhibitor]."

Campbell and colleagues will be conducting a follow-up of prescribing data through 2019, which will of course include the newer agents. They'll also investigate reasons for drug discontinuation and outcomes of those who discontinue versus continue metformin.

Campbell has reported no relevant financial relationships. Flory consults for a legal firm on litigation related to insulin analog pricing issues, not for or pertaining to a specific company.

Diabet Med. Published online June 16, 2021. Abstract

Miriam E. Tucker is a freelance journalist based in the Washington DC area. She is a regular contributor to Medscape, with other work appearing in the Washington Post, NPR's Shots blog, and Diabetes Forecast magazine. She is on Twitter: @MiriamETucker.

For more diabetes and endocrinology news, follow us on Twitter and Facebook.

See the original post:
Half Abandon Metformin Within a Year of Diabetes Diagnosis - Medscape

Read More...

Diabetes prevention: How is okra beneficial for Diabetes? Can it help lower blood sugar? – Times of India

August 4th, 2021 1:54 am

Okra, otherwise known as ladyfinger, is a green flowering plant and belongs to the same plant family as hibiscus and cotton.

Apart from its amazing taste, it is filled with nutrients and minerals that are essential for the body. It has a reputation as a superfood as it is a blessing for those with diabetes or cancer. It has potassium, vitamin B, vitamin C, folic acid, and calcium. It is also low in calories and has a high fibre content.

Here is what makes okra beneficial for diabetics.

It was found that okra is very beneficial for the early stages of diabetes. The research found that people who consumed okra water reported decreasing blood sugar levels and roasted Okra seeds have been used for years as a medicine in Turkey to treat diabetes.

See more here:
Diabetes prevention: How is okra beneficial for Diabetes? Can it help lower blood sugar? - Times of India

Read More...

Hypoglycemia and type 2 diabetes: Link, signs, what to do – Medical News Today

August 4th, 2021 1:54 am

People with type 2 diabetes may experience hypoglycemia if their blood sugar levels drop too low. They can treat this by consuming the right amount of suitable types of carbohydrates. However, severe hypoglycemia is a medical emergency.

There are numerous misconceptions about hypoglycemia and type 2 diabetes. According to a 2020 review, people have believed that hypoglycemia cannot occur in people with type 2 diabetes or that it cannot have serious consequences.

Authors of the review found that as many as 25% of people with type 2 diabetes who have taken insulin for 5 years may experience severe hypoglycemia. The researchers also noticed a similar prevalence in people with type 1 diabetes.

This article explains what hypoglycemia is and how it may affect someone with type 2 diabetes. It discusses symptoms and treatment and what to do in severe hypoglycemia. It also discusses strategies to prevent blood sugar from dropping too low.

Hypoglycemia, or low blood sugar, occurs when the level of glucose in the blood becomes insufficient. Doctors may also refer to low blood sugar as insulin reaction or insulin shock.

According to the American Diabetes Association (ADA), blood sugar levels can rise and fall naturally. Typically, a person will not be able to notice this if blood sugar stays within normal ranges. However, if it drops below a certain level and a person does not seek treatment, it can be dangerous.

Learn more about hypoglycemia here.

For most people with diabetes, hypoglycemia means their glucose level has dropped to 70 milligrams per deciliter (mg/dl) or less. This is equivalent to a blood sugar concentration of 3.9 millimoles per liter.

Hypoglycemia is most common in people who use insulin, such as those with type 1 diabetes.

However, people with type 2 diabetes are also increasingly using insulin, which can mean the prevalence of hypoglycemia among this group may be on the rise.

Hypoglycemia is also common in people who take medication to reduce high blood sugar. This is because, due to certain factors, people need less insulin than they thought and cause their blood sugar to drop too low.

These factors include:

Learn how low blood sugar can affect the body here.

The National Institute of Diabetes and Digestive Kidney Diseases (NIDDK) lists the following causes of hypoglycemia in people with type 2 diabetes:

Some type 2 diabetes medications can increase a persons likelihood of developing hypoglycemia, such as:

A person should contact a doctor if their diabetes medication is having this effect. They should not stop taking their medication without advice from a doctor.

The digestive system breaks down carbohydrates into glucose, which raises blood sugar levels.

Individuals need to eat enough carbohydrates to balance their medication and avoid hypoglycemia. They should therefore seek guidance from a healthcare professional about how to reach that balance.

Additionally, the protein, fat, and fiber content in meals affects the absorption of carbohydrates and can slow down the release of blood sugar into the bloodstream.

Skipping or delaying meals can cause a persons blood glucose to drop too low.

Furthermore, hypoglycemia can occur while a person is sleeping and has not eaten for several hours.

If a person increases their physical activity beyond what they typically do, it can lower their blood glucose level for up to 24 hours after the activity.

A person can always discuss possible increases in physical activity with a doctor to find an exercise plan suitable for them.

If a person is feeling nauseous or vomiting, they may not be consuming as much food as they usually would. This can lead to lower blood glucose levels.

A person may try to have simple broths, sodas, or ice pops to keep their blood sugar stable. However, if sickness continues or if they have hypoglycemia, they should seek medical attention.

If someone with diabetes drinks alcohol when they have not eaten for a while, it can lead to hypoglycemia.

The effects of drinking alcohol may also make it more difficult to notice the symptoms of low blood sugar, and lead to severe hypoglycemia.

Symptoms of hypoglycemia can vary from person to person. In some people, there may be no symptoms, while in others, they may appear suddenly.

Signs and symptoms of mild to moderate hypoglycemia include:

With severe hypoglycemia, a person may:

A person experiencing any symptoms of severe hypoglycemia should seek emergency medical care.

A person can also experience symptoms of hypoglycemia in their sleep. These include:

Learn more about the signs of low blood sugar here.

If a person has symptoms of hypoglycemia, they should check their blood glucose. They can use at-home methods, such as the 15-15 rule, to improve mild hypoglycemia.

However, a person experiencing severe hypoglycemia should seek emergency medical care.

Additionally, individuals who take insulin should teach people close to them to use emergency glucagon on them in hypoglycemic emergencies.

According to the ADA, a person with hypoglycemia can have 15 grams (g) of carbohydrates to raise their blood sugar, and should recheck their levels after 15 minutes.

If blood glucose is still below 70 mg/dl, they should have another serving and repeat the process until their blood sugar is within the normal range again.

Examples of 15 g of suitable carbohydrates include:

If the persons next meal is more than 1 hour away, they should also have a snack, such as crackers or fruit, to keep their blood sugar levels within their target range.

The NIDDK notes that people who have kidney disease should avoid drinking orange juice for their 15 g of carbohydrates, as it contains a lot of potassium. Instead, they could have apple, grape, or cranberry juice.

Learn more about what to eat for hypoglycemia here.

Anyone who uses insulin should wear a medical pendant or bracelet to alert others that they may need help during emergencies such as hypoglycemia.

Additionally, people with diabetes should let their family and friends know how to administer emergency glucagon.

If a person loses consciousness, they may have severe hypoglycemia. If this is the case, another person needs to treat them straight away, as lack of glucose supply to the brain can cause a coma, seizure, or, more rarely, death.

If a person has severe hypoglycemia, they will need an injection of glucagon in their buttock, arm, or thigh to raise their blood glucose level.

People with diabetes should consult a doctor about when and how to use an emergency glucagon kit, and make sure that it has not expired by checking the date.

Sometimes, doctors also prescribe glucagon that another individual can puff into the persons nostril.

If someone with diabetes has severe hypoglycemia, another person should not hesitate to call 911, especially if they do not know how to use an emergency glucagon kit.

If a person with diabetes is having symptoms so severe that they cannot treat themselves, such as losing consciousness, others should not inject them with insulin, as this will lower their blood glucose further.

Additionally, they should not give them food or fluids, as the person may choke.

People taking diabetes medication should work with their healthcare team to develop a management plan to prevent hypoglycemia.

Additionally, the following strategies may help avoid low blood sugar:

Regularly monitoring blood glucose levels may also lower a persons risk of developing complications from hypoglycemia.

A 2020 review suggests that some people who have had hypoglycemic episodes may not inform a doctor about the event or may not remember it well enough to relay their experiences properly.

It is important that a person informs a doctor of any hypoglycemic events they have experienced. The following actions may help a person with diabetes:

Hypoglycemia unawareness refers to when a person is unaware that their blood sugar is too low. As a result, they may feel no symptoms and be more at risk of severe hypoglycemia. Additionally, it may be difficult for them to wake up from sleeping.

People with hypoglycemia unawareness need to take extra care to check their blood sugar levels, especially before carrying out tasks such as driving.

Hypoglycemia can occur in people with type 2 diabetes when their blood sugar levels fall too low. In many people, this means 70 mg/dl or less, although this can vary from person to person.

Individuals with type 2 diabetes can treat hypoglycemia by consuming 15 g of a suitable carbohydrate and checking their blood sugar levels until they normalize.

Severe hypoglycemia may cause seizures or unconsciousness. Therefore, people with type 2 diabetes who use insulin should ensure they have an emergency glucagon kit and that people closest to them know how to use it.

A person should not hesitate to call 911 if they are unsure what to do when they are with someone who has severe hypoglycemia.

Read more:
Hypoglycemia and type 2 diabetes: Link, signs, what to do - Medical News Today

Read More...

Have You Tried Millet? Research Finds Promising Blood Sugar Benefits – mindbodygreen.com

August 4th, 2021 1:54 am

Based on the review, eating millets may actually reduce the risk of developing type 2 diabetes. On top of that, researchers found it helped manage blood glucose levels for people with diabetes.

Millets have a relatively low average glycemic index (GI), especially when compared to other grains. (A food's GI basically gives a number to how much and how quickly a food will spike blood sugar.) With a GI of 52.7 on average, that's significantly lower than rice, corn, and refined wheat. According to the research, those levels remained low to medium, regardless of how the grain was cooked.

Plus, the researchers found diabetic people who atemillet on a daily basissaw a decrease in blood glucose levels, with some even getting into the prediabetes range. They observed similar benefits in people with prediabetes.

As lead author of the study Seetha Anitha, Ph.D., states in a news release, "This systematic review of the studies published in scientific journals has proven that millets can keep blood glucose levels in check and reduce the risk of diabetes. It has also shown just how well these smart foods do it."

Read more here:
Have You Tried Millet? Research Finds Promising Blood Sugar Benefits - mindbodygreen.com

Read More...

Mainers with diabetes encouraged to participate in free ‘Living Well with Diabetes’ workshop – The Original Irregular

August 4th, 2021 1:54 am

By IrregStaff | on August 04, 2021

Examples of topics covered in the workshop include:

* Techniques to deal with the symptoms of diabetes such as fatigue, pain, hyper/hypoglycemia, stress, depression, anger, fear and frustration

* Appropriate exercise for maintaining and improving strength and endurance

* Healthy eating

* Appropriate use of medication

* Guidance on working with healthcare providers

Living Well with Diabetes is offered via Zoom and is open to adults of any age in Maine dealing with diabetes and its symptoms. Caregivers and/or supports of those living with diabetes are also encouraged to register. Additionally, people who would like to join the workshop but do not have access to the necessary technology may be eligible to borrow a device through Healthy Living for Maines iPad loaning program in order to participate in the workshop.

Living Well with Diabetes is scheduled to begin Tuesday, Aug. 10, 2021, and will meet each Tuesday for six weeks. Later in the fall, Healthy Living for Maine will also be offering Living Well with Diabetes for additional six-week sessions, with one beginning Friday, Oct. 8, 2021, and another beginning Tuesday, Nov. 9, 2021. Registration for each of these series is now open, including the associated phone versions (not listed).

This series is free for any adult Mainer dealing with diabetes, but advance registration is required. Contact Healthy Living for ME at 1-800-620-6036 orinfo@healthylivingforme.orgfor more information and to register. You can also register via websitewww.healthylivingforme.org.

To learn more about this, and other workshops offered by Healthy Living for ME, visitwww.healthylivingforme.org.

View post:
Mainers with diabetes encouraged to participate in free 'Living Well with Diabetes' workshop - The Original Irregular

Read More...

Dear Abbey: Diabetes Monitor is More Than The Hassle Of The Office | Dear Abbey – Illinoisnewstoday.com

August 4th, 2021 1:54 am

Dear Abbey: Disturbed in Texas (June 5th) was plagued by the frequent buzzing of a diabetic colleague. Disturbed may not fully understand this situation. A buzzer is a continuous blood glucose monitor (CGM) that alerts insulin-dependent diabetics of out-of-range blood glucose levels. Prompt action may be required to correct these blood sugar levels, and it is important for diabetics to receive these warnings.

Yes, if possible, CGM should be vibrated in public so that it does not get in the way of others. But in some situations it is not impossible or wise. Neuropathy can be desensitizing, and active environments can make vibrations undetectable. I also wonder about the frequency of these beeps. In my experience, the alarm sounds an average of 2-5 times in 24 hours. This is just a few short beeps that can be canceled when the diabetics realize that they need to be treated for glucose.

In my opinion, this is less annoying than the interruption of many offices-water cooler gossip, a phone ringing in the cubicle next door, a neighbor with a lively cold, etc. Insulin-dependent diabetes mellitus is a relentless illness. There is no break. (I know this directly. I care for a child with type 1 diabetes who is not old enough to respond appropriately to the alarm.)

Diabetes should not be used as an excuse to annoy others, but on the other hand, people with diabetes and other chronic illnesses also need to understand a little. Life can be very difficult. The best way to gain understanding can be to educate. I would like to do this with this submission. Thank you, Abbey. -Sensitive in South Dakota

Dear Sensitive: No, readers, thank you for taking the time to explain this to me and my readers. I now have a better understanding of how complex the process of managing diabetes can be. And I agree that it can be important to cut a little slack for others.

Dear Abbey: We have a garage sale every year. I have good friends who are not only unhelpful but also hoping to put her stuff up for sale. Then Im responsible for tracking her items and finally paying her. Sometimes she put up high-priced items like boats, and I have to call her whenever there is a lower offer. How can I tell her to do her garage sale without causing hurt feelings? -Unloading in Michigan

Dear Unload: Your friends are very nervous. Tell her she should have her own unless she is willing to help you in the garage sale and track her own items. Alternatively, I suggest taking a percentage of the money her item brings-its important to compensate for your work. Dont worry about hurt her feelings. She has a thick skin.

Dear Abbey, was written by Abigail Van Buren, also known as Jeanne Phillips, and founded by her mother, Pauline Phillips.Contact Dear Abbey http://www.DearAbby.com Or PO Box 69440, Los Angeles, CA90069.

Deliver local news to your inbox!

Dear Abbey: Diabetes Monitor is More Than The Hassle Of The Office | Dear Abbey

Source link Dear Abbey: Diabetes Monitor is More Than The Hassle Of The Office | Dear Abbey

More:
Dear Abbey: Diabetes Monitor is More Than The Hassle Of The Office | Dear Abbey - Illinoisnewstoday.com

Read More...

Do you have hidden diabetes? The 15 signs to watch out for… – The US Sun

August 4th, 2021 1:54 am

MORE people than ever are at risk of diabetes - and some may be developing it without a clue.

Charities have warned the UK is facing a diagnosis timebomb after many people missed vital GP appointments during the pandemic.

1

Already some 4.9 million people in the UK are estimated to have diabetes, of which there are various forms.

But of those, some 850,000 people are living with type 2 diabetes but are yet to be diagnosed - a figure up 150,000 in the last year, according to Diabetes UK.

Staggering stats reveal people can live for up to 10 years with type 2 diabetes - the most common type - before being diagnosed.

On top of this, some 2.1 million people have a blood sugar level that is higher than normal, but not bad enough to be diagnosed with diabetes.

This is called prediabetes, or borderline diabetes, and means a person is on track to get a diagnosis if they dont act fast.

There are likely to be many more who are not aware they are in this category.

A further 13.6 million people in the UK are at risk of developing type 2 diabetes - but many will not know.

These people are overweight - the key driver of type 2 diabetes. Having a family member with the disease or being African-Carribean are also example of risk factors.

These people can start making changes, such as eating healthier, to prevent a diagnosis as early as possible.

Meanwhile, the pandemic has had a huge impact on people already living with a diagnosis.

Diabetes is a complex disease to manage. But concerning figures show nearly 2.5million people already with the condition missed vital checks over Covid.

GPs have performed 41 per cent fewer health checks in the last year, analysis by Diabetes UK found in June.

The backlog could be putting sufferers at risk of Covid death, heart attacks and strokes among other complications.

The total number of cases of diabetes is expected to reach 5.5 million people by 2030.

Diabetes UK chief executive Chris Askew said: We're sitting on a diabetes timebomb. Missed appointments and missed or delayed diagnoses can devastate lives.

Prediabetes is a grey area.

It is when someones blood glucose levels are higher than normal but not yet high enough to be classed as diabetes.

In the UK, around 7 million people are estimated to have prediabetes, according to Diabetes.co.uk.

People often dont notice the symptoms and put them down to something else, such as their stress levels or their age

Experts say prediabetes is a critical stage in the development of the disease because this is when people still have the ability to slow down, or even halt, the condition.

But prediabetes has no symptoms, Dr Prash Vas, consultant in Diabetes at London Bridge Hospital, told The Telegraph.

He said: [Prediabetes] has no symptoms. As your blood sugar levels go higher, the body will mount symptoms.

Even this group of individuals can have complications, such as a three times higher risk of developing eye problems such as diabetic retinopathy. There is also an increased chance of developing kidney problems and early nerve damage.

According to Dan Howarth, head of care at Diabetes UK, symptoms of diabetes wont kick in till blood sugar levels are around 11mmol/L, even though anything above 7.8mmol/L after eating is considered too high.

Even then, people often dont notice the symptoms and put them down to something else, such as their stress levels or their age, Dr Howarth said.

If your doctor is concerned you have pre-diabetes they will usually do either a HbA1c test, a fasting plasma glucose (FPG) test, or an OGTT test.

The NHS says type 2 diabetes is often diagnosed following blood or urine tests for something else.

Symptoms of diabetes can go completely missed because people think they are caused by something else.

Or their symptoms dont necessarily make them feel unwell, so they are not even acknowledged.

The most common early signs of type 2 diabetes are frequent urination, extreme thirst, and persistent hunger.

You should visit your GP if you are:

There are other symptoms that may alert you to this disease.

These include:

Factors such as age, family history and ethnicity can increase a persons likelihood of having diabetes.

The condition usually develops slowly when someone is over the age of 40 years old.

However, the risk starts increasing from the age of 25 if you are African-Caribbean, Black African, or South Asian.

Generally studies have found that people of African-Caribbean, black African or south Asian descent are two to four times more likely to develop type 2 diabetes than those from a white background.

Obesity is fuelling type 2 diabetes, accounting for 80 to 85 per cent of someones chances of developing the condition.

Just because you have one or more risk factors for diabetes, it doesnt mean you will get it.

However, its best to be wary so that you can prevent the condition now. Because the symptoms of type 2 diabetes are not always obvious, its really important to be aware of these risk factors, charities say.

Risk factors include if you:

You can take the "Know Your Risk" for type 2 diabetes quiz to find out your risk of getting type 2 diabetes.

The rapid quiz asks about age, weight, if someone in the family has diabetes and if you have been told you have high blood pressure, for example.

It will then give a score between zero and 47 points.

The higher the risk level, the more likely it is that person will develop type 2 diabetes in the next 10 years. For example, one out of four people with high risk will get type 2 diabetes in the next 10 years.

If someones score is moderate or high they can refer themselves to a local service for support remotely or online, without having to go through a healthcare professional.

Read the original post:
Do you have hidden diabetes? The 15 signs to watch out for... - The US Sun

Read More...

Impel NeuroPharma to Present at the 2021 Wedbush Pacgrow Virtual Healthcare Conference

August 4th, 2021 1:53 am

SEATTLE, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that Adrian Adams, chief executive officer, will present on a panel titled “For Headaches THIS Big – The Evolution of Migraine Therapeutic Landscape” at the 2021 Wedbush Pacgrow Virtual Healthcare Conference on Tuesday, August 10, 2021 at 8:00-8:30 a.m. ET.

See the article here:
Impel NeuroPharma to Present at the 2021 Wedbush Pacgrow Virtual Healthcare Conference

Read More...

Aptose Reports Results for the Second Quarter 2021

August 4th, 2021 1:53 am

- Conference call and webcast at 5:00 pm EDT today -

See the rest here:
Aptose Reports Results for the Second Quarter 2021

Read More...

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

August 4th, 2021 1:53 am

NEWTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the granting of inducement awards to two new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were made as a material inducement to each employee’s entry into employment with the Company.

See the article here:
Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read More...

Pacific Biosciences of California, Inc. Announces Second Quarter 2021 Financial Results

August 4th, 2021 1:53 am

MENLO PARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2021.

See original here:
Pacific Biosciences of California, Inc. Announces Second Quarter 2021 Financial Results

Read More...

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

August 4th, 2021 1:53 am

FOSTER CITY, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that management will be participating in a liver disease panel at the 2021 Wedbush PacGrow Healthcare Conference on Tuesday, August 10 at 2:20pm ET. Terns management will also present at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11 at 1:00pm ET.

Originally posted here:
Terns Pharmaceuticals to Present at Upcoming Investor Conferences

Read More...

Gain Therapeutics to Present at the BTIG Virtual Biotechnology Conference

August 4th, 2021 1:53 am

BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing novel allosteric binding sites on proteins responsible for neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present a corporate overview at the BTIG Virtual Biotechnology Conference being held on August 9 – 10.

Excerpt from:
Gain Therapeutics to Present at the BTIG Virtual Biotechnology Conference

Read More...

Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference

August 4th, 2021 1:53 am

EMERYVILLE, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Chief Financial Officer, will participate in a virtual fireside chat on Tuesday, August 10, 2021, at the BofA SMID Cap 2H21 Ideas Conference.

Read the rest here:
Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference

Read More...

Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

August 4th, 2021 1:53 am

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences:

See original here:
Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

Read More...

GBT Reports Second Quarter 2021 Financial Results

August 4th, 2021 1:53 am

Achieved Oxbryta® (voxelotor) net revenues of $47.6 million, an increase of 51% year-over-year

Originally posted here:
GBT Reports Second Quarter 2021 Financial Results

Read More...

Page 181«..1020..180181182183..190200..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick